Product information and disease descriptionProduct descriptionProduct information
Product comparison
27 evidence topics · 6 sources
Approval basis and labeled population compared with the two other approved NPC treatments
Arimoclomol: U.S. indication
Arimoclomol: recommended oral dosage by actual body weight, in combination with miglustat
| Actual body weight | Prescribing information |
|---|---|
| 8 kg to 15 kg | “8 kg to 15 kg, is 47 mg three times a day” |
| More than 15 kg to 30 kg | “15 kg to 30 kg, is 62 mg three times a day” |
| More than 30 kg to 55 kg | “30 kg to 55 kg, is 93 mg three times a day” |
| More than 55 kg | “55 kg, is 124 mg three times a day” |
Arimoclomol: dosage forms, packaging, and national drug codes
| Strength | Package configuration | NDC |
|---|---|---|
| 47 mg | “Bottle of 90 capsules” | “72542-147-01” |
| 62 mg | “Bottle of 90 capsules” | “72542-162-01” |
| 93 mg | “Bottle of 90 capsules” | “72542-193-01” |
| 124 mg | “Bottle of 90 capsules” | “72542-124-01” |
Arimoclomol: oral and feeding tube administration
Arimoclomol: warnings and precautions
Arimoclomol: adverse reactions in Trial 1
Arimoclomol: adverse reactions in at least 8% of treated participants who also received miglustat in Trial 1
Arimoclomol: drug interaction with OCT2 substrates
Arimoclomol: pediatric and geriatric use
Levacetylleucine: U.S. indication in Niemann-Pick disease type C
Levacetylleucine: basis of the dosage and packet strength
Levacetylleucine: granules for oral suspension, strength and appearance
Levacetylleucine: warning for embryo-fetal toxicity
Levacetylleucine: adverse reactions in NPC, safety population and exposure in Trial 1
Levacetylleucine: rosacea and thrombocytopenia in NPC Trial 1
Levacetylleucine: pediatric use in NPC and supporting pharmacokinetic data
Miglustat: U.S. labeled indication limited to type 1 Gaucher disease
Miglustat: European Union indication and dosage in Niemann-Pick type C disease
Miglustat: European Union dose by body surface area in Niemann-Pick type C disease, patients under 12 years
| Body surface area (m2) | Recommended dose |
|---|---|
| More than 1.25 | “200 mg three times a day” |
| More than 0.88 to 1.25 | “200 mg twice a day” |
| More than 0.73 to 0.88 | “100 mg three times a day” |
| More than 0.47 to 0.73 | “100 mg twice a day” |
| 0.47 or less | “100 mg once a day” |